The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol
Open accessAbstract
Objectives This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF).Background It is unknown whether angiotensin II receptor blockade is better than beta-blockade in preventing new-onset AF.Methods In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy. Electrocardiograms were Minnesota coded centrally, and 8,851 patients without AF by electrocardiogram or history, who were thus at risk of developing AF, were followed for 4.8 +/- 1.0 years.Results New-onset AF occurred in 150 patients randomized to losartan versus 221 to atenolol (6.8 vs. 10.1 per 1,000 person-years; relative risk 0.67, 95% confidence interval [CI] 0.55 to 0.83, p < 0.001) despite similar blood pressure reduction. Patients receiving losartan tended to stay in sinus rhythm longer (1,809 +/- 225 vs. 1,709 +/- 254 days from baseline, p = 0.057) than those receiving atenolol. Moreover, patients with new-onset AF had two-, three- and fivefold increased rates, respectively, of cardiovascular events, stroke, and hospitalization for heart failure. There were fewer composite end points (n = 31 vs. 51, hazard ratio = 0.60, 95% CI 0.38 to 0.94, p = 0.03) and strokes (n = 19 vs. 38, hazard ratio = 0.49, 95% CI 0.29 to 0.86, p = 0.01) in patients who developed new-onset AF in the losartan compared to the atenolol treatment arm of the study. Furthermore, Cox regression analysis showed that losartan (21% risk reduction) and new-onset AF both independently predicted stroke even when adjusting for traditional risk factors.Conclusions Our novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Secondary analyses of ACE inhibitors or ARBs in patients with heart failure or LVH show a lower incidence of new-onset AF.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [246]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01236-6 · Cited by 1,562
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L., ASINGER, R. W., Cannom, D. S., Crijns, H. J. G. M., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,362
Left Atrial Size and the Risk of Stroke and Death
Benjamin, E. J., D’Agostino, R. B., Belanger, A. J., Wolf, P. A., & Levy, D. A. (1995) · Circulation · doi:10.1161/01.cir.92.4.835 · Cited by 1,058
Li, D., Shinagawa, K., Pang, L., Leung, T. K., Cardin, S., Wang, Z., & Nattel, S. (2001) · Circulation · doi:10.1161/hc4601.099402 · Cited by 702
Madrid, A. H., Bueno, M. G., Rebollo, J. M. G., Marín, I., Peña, G., Bernal, E., Rodriguez, A., Cano, L., Cano, J. M., Cabeza, P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000022665.18619.83 · Cited by 685
Pedersen, O. D., Bagger, H., Køber, L., & Torp-Pedersen, C. T. (1999) · Circulation · doi:10.1161/01.cir.100.4.376 · Cited by 656
Vermès, E., Tardif, J., Bourassa, M. G., Racine, N., Lévesque, S., White, M., Guerra, P. G., & Ducharme, A. (2003) · Circulation · doi:10.1161/01.cir.0000072793.81076.d4 · Cited by 575
Kumagai, K., Nakashima, H., Urata, H., Gondo, N., Arakawa, K., & Saku, K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00464-9 · Cited by 472
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 819
Inhibition of the Renin-Angiotensin System and the Prevention of Stroke
Schrader, J., Kulschewski, A., & Dendorfer, A. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707010-00003 · Cited by 29
Latif, S. R., Nguyen, V. Q., Peters, D. C., Soufer, A., Henry, M. L., Grunseich, K., Testani, J. M., Hur, D. J., Huber, S., Mojibian, H. R., et al. (2019) · International journal of cardiac imaging · doi:10.1007/s10554-019-01551-7 · Cited by 28
Disertori, M., Barlera, S., Staszewsky, L. I., Latini, R., Quintarelli, S., & Franzosi, M. G. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6346-0 · Cited by 28
Hypertension and atrial fibrillation
Middeldorp, M. E., Ariyaratnam, J., Kamsani, S. H., Albert, C. M., & Sanders, P. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003278 · Cited by 27
Sato, Y., Fujii, S., Imagawa, S., Ohmura, K., Ohmura, Y., Andoh, Y., Dong, J., Ishimori, N., Furumoto, T., & Tsutsui, H. (2007) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14.31 · Cited by 27
Upstream therapy of atrial fibrillation
Smit, M. D., & Gelder, I. C. V. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.59 · Cited by 27
Comparing angiotensin II receptor blockers on benefits beyond blood pressure
Siragy, H. M. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0028-3 · Cited by 27
Yamauchi, T., Sakata, Y., Miura, M., Onose, T., Tsuji, K., Abe, R., Oikawa, T., Kasahara, S., Sato, M., Nochioka, K., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-16-0759 · Cited by 27
Moen, M. D., & Wagstaff, A. J. (2005) · Drugs · doi:10.2165/00003495-200565180-00012 · Cited by 27
LALLY, J. A., Gnall, E., Seltzer, J. H., & Kowey, P. R. (2007) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2007.00874.x · Cited by 27
Wachtell, K., Devereux, R. B., Lyle, P. A., Okin, P. M., & Gerdts, E. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708093846 · Cited by 27
Self-citationProlonged QTc Interval Predicts Poststroke Paroxysmal Atrial Fibrillation
Hoshino, T., Nagao, T., Shiga, T., Maruyama, K., Toi, S., Mizuno, S., Ishizuka, K., Shimizu, S., Uchiyama, S., & Kitagawa, K. (2014) · Stroke · doi:10.1161/strokeaha.114.006612 · Cited by 26
Genetically Predicted Blood Pressure and Risk of Atrial Fibrillation
Hyman, M. C., Levin, M. G., Gill, D., Walker, V. M., Georgakis, M. K., Davies, N. M., Marchlinski, F. E., & Damrauer, S. M. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16191 · Cited by 27
Galzerano, D., Michele, S. D., Paolisso, G., Tuccillo, B., Lama, D., Carbotta, S., Cittadini, A., Tedesco, M. A., & Gaudio, C. (2012) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320312443909 · Cited by 26
Zhang, C., Yasuno, S., Kuwahara, K., Zankov, D. P., Kobori, A., Makiyama, T., & Horie, M. (2006) · Circulation Journal · doi:10.1253/circj.70.335 · Cited by 26
Weir, M. R., & Bakris, G. L. (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.07439.x · Cited by 26
Upstream therapies to prevent atrial fibrillation
Dorian, P., & Singh, B. N. (2008) · European Heart Journal Supplements · doi:10.1093/eurheartj/sun033 · Cited by 26
New antiarrhythmic treatment of atrial fibrillation
Naccarelli, G. V., Wolbrette, D. L., Samii, S. M., Banchs, J. E., Penny-Peterson, E., & Gonzalez, M. D. (2007) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.5.4.707 · Cited by 26
Reverse Atrial Remodeling in Heart Failure With Recovered Ejection Fraction
Sun, Y., Chen, X., Zhang, Y., Yao, Y. H., Zhang, X., Si, J., Ding, Z., Xia, Y., Tse, G., & Liu, Y. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.026891 · Cited by 25
Cardiometabolic Risk Factors and Atrial Fibrillation
Menezes, A. R., Lavie, C. J., DiNicolantonio, J. J., O’Keefe, J. H., Morin, D. P., Khatib, S., Messerli, F. H., & Milani, R. V. (2013) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0693 · Cited by 25
Lin, T., Yang, Y., Liao, M., Tsai, C., Hwang, J., Chiang, F., Chen, P., Lin, J.-L., & Lin, L. (2015) · Kidney International · doi:10.1038/ki.2015.96 · Cited by 25
Das Herz bei arterieller Hypertonie
Hennersdorf, M., & Strauer, B. E. (2006) · Der Internist · doi:10.1007/s00108-006-1762-0 · Cited by 25
Lin, X., Wu, N., Shi, Y., Wang, S., Tan, K. W., Shen, Y., Dai, H., & Zhong, J. (2014) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2014.913600 · Cited by 24
Larstorp, A. C. K., Stokke, I. M., Kjeldsen, S. E., Olsen, M. H., Okin, P. M., Devereux, R. B., & Wachtell, K. (2019) · Blood Pressure · doi:10.1080/08037051.2019.1633905 · Cited by 25
Self-citationDing, Y., Ma, Y., Qian, L.-Y., Xu, Q., Wang, L., Huang, D., & Zou, H. (2017) · Oncotarget · doi:10.18632/oncotarget.19522 · Cited by 24
Lehtonen, A. O., Langén, V. L., Porthan, K., Kähönen, M. A. P., Nieminen, M. S., Jula, A., & Niiranen, T. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001760 · Cited by 24
Self-citationDeng, H., Shantsila, A., Xue, Y., Bai, Y., Guo, P., Potpara, T., Zhan, X., Fang, X., Liao, H., Wu, S., et al. (2019) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2019.02.006 · Cited by 24
Shinohara, Y., Yanagihara, T., Abe, K., Yoshimine, T., Fujinaka, T., Chuma, T., Ochi, F., Nagayama, M., Ogawa, A., Suzuki, N., et al. (2011) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2011.05.003 · Cited by 23
The cardiovascular continuum refined: A hypothesis
Volpe, M., Camm, A. J., Coca, A., & Unger, T. (2010) · Blood Pressure · doi:10.3109/08037051.2010.481072 · Cited by 23
Marazzato, J., Blasi, F., Golino, M., Verdecchia, P., Angeli, F., & Ponti, R. D. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9040110 · Cited by 23
Biomarkers in Atrial Fibrillation, Ventricular Arrhythmias, and Sudden Cardiac Death
Mountantonakis, S., & Deo, R. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00238.x · Cited by 23
Pan, G., Zhou, X., & Zhao, J. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12073 · Cited by 23
Renin–angiotensin–aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy
Huang, C., Yang, Y., Lin, L., Tsai, C., Hwang, J., Chen, P., & Lin, J.-L. (2018) · Heart · doi:10.1136/heartjnl-2017-312573 · Cited by 23
Choudhury, A., Varughese, G. I., & Lip, G. Y. H. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.13.2193 · Cited by 23
Lifestyle changes in atrial fibrillation management and intervention
Yang, L., & Chung, M. K. (2023) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.15803 · Cited by 22
Depression and atrial fibrillation in a reciprocal liaison: a neuro-cardiac link
Manolis, T. A., Manolis, A. S., Apostolopoulos, E. J., Melita, H., & Manolis, A. S. (2023) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2023.2248214 · Cited by 22
Tsai, C., Chiang, F., Chen, W., Hwang, J., Tseng, C.-D., Wu, C., Yu, C., Wang, Y., Lai, L., & Lin, J.-L. (2010) · Cell Calcium · doi:10.1016/j.ceca.2010.10.005 · Cited by 22
Watanabe, T., Kawasaki, M., Tanaka, R., Ono, K., Nishigaki, K., Takemura, G., Arai, M., Noda, T., Watanabe, S., & Minatoguchi, S. (2013) · Hypertension Research · doi:10.1038/hr.2013.25 · Cited by 22
Atrial Remodeling And Atrial Fibrillation: Mechanistic Interactions And Clinical Implications
Hassan, W., & Al-Ghamdi, B. S. (2009) · Journal of Atrial Fibrillation · doi:10.4022/jafib.v1i7.537 · Cited by 22
Atrial fibrillation: insights from clinical trials and novel treatment options
Blaauw, Y., & Crijns, H. J. G. M. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01885.x · Cited by 22
Levels of PAI-1 and outcome after electrical cardioversion for atrial fibrillation
Tveit, A., Seljeflot, I., Grundvold, I., Abdelnoor, M., Smith, P., & Arnesen, H. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2007.06.014 · Cited by 21
der Niepen, P. V., Giot, C., & van de Borne, P. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e32830a9a49 · Cited by 21
Platonov, P. G., Cygankiewicz, I., Stridh, M., Holmqvist, F., Vázquez, R., Bayés‐Genís, A., McNitt, S. A., Zaręba, W., & Bayés‐Genís, A. (2012) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.111.964395 · Cited by 21
Evaluation of Left Atrial Degeneration for the Prediction of Atrial Fibrillation
Kubota, T., Kawasaki, M., Takasugi, N., Takeyama, U., Ishihara, Y., Okubo, M., Yamaki, T., Ojio, S., Aoyama, T., Arai, M., et al. (2009) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2009.03.021 · Cited by 21
Papademetriou, V. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.04.006 · Cited by 21
Palardy, M., Ducharme, A., Nattel, S., Tardif, J., White, M., Racine, N., Tétreault, K., Dabouz, F., Talajic, M. R., & Roy, D. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)70670-6 · Cited by 21
Hypertension associated with atrial fibrillation
Aronow, W. S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.10.33 · Cited by 21
2023 Guideline for the management of hypertension in the elderly population in China
Hua, Q., Fan, L., Wang, Z., & Li, J. (2024) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2024.06.001 · Cited by 21
A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention
Wang (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6203 · Cited by 20
Managing hypertension in cardiology practice according to risk profile
Volpe, M., & Tocci, G. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01821.x · Cited by 20
Anti-arrhythmic properties of non-antiarrhythmic medications
Williams, E. A., Russo, V., Ceraso, S., Gupta, D., & Barrett‐Jolley, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104762 · Cited by 20
Katsiki, N., Tsioufis, K. P., Ural, D., & Volpe, M. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13325 · Cited by 20
Güler, N., Özkara, C., Dülger, H., Kutay, V., Şahin, M., Erbilen, E., & Gümrükçüoğlu, H. A. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2006.08.040 · Cited by 20
Informe del Grupo de Trabajo para la elaboración de guías de práctica clínica del American College of Cardiology y de la American Heart Association, del Comité de Guías de Práctica Clínica de la Sociedad Europea de Cardiología (comité de redacción para la revisión de la Guía de práctica clínica sobre el manejo de pacientes con fibrilación auricular, 2., & Desarrollado en colaboración con las asociaciones European Heart Rhythm Association y Heart Rhythm Society (2006) · Revista Española de Cardiología · doi:10.1157/13096583 · Cited by 20
Guo, X., Li, N., Du, X., Bai, R., Yu, R., Long, D., Tang, R., Sang, C., Jiang, C., Ning, M., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.09.011 · Cited by 19
Atrial fibrillation and chronic heart failure: interrelationship and approaches to treatment
Gagloeva, D. A., Mironov, N. Y., Laiovich, L. I., Миронова, Н. А., & Sp, G. (2021) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin2021160215 · Cited by 19
Habel, N., Infeld, M. M., Bernknopf, J., Meyer, M., & Lustgarten, D. L. (2023) · Heart Rhythm O2 · doi:10.1016/j.hroo.2023.12.001 · Cited by 19
Evidence for benefits of angiotensin receptor blockade beyond blood pressure control
Siragy, H. M. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0050-x · Cited by 19
Yamashita, T., Ogawa, S., Aizawa, Y., Atarashi, H., Inoue, H., Ohe, T., Okumura, K., Ohtsu, H., Kato, T., Kamakura, S., et al. (2006) · Circulation Journal · doi:10.1253/circj.70.1318 · Cited by 19
Diretriz Brasileira de Fibrilação Atrial – 2025
Cintra, F. D., Pisani, C. F., Rezende, A. G. D. S., Henz, B. D., Armaganijan, L., Pimentel, M., Lópes, R. D., do Nascimento, T. A., Lorga-Filho, A. M., de Albuquerque, A., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250618 · Cited by 21
Atrial Fibrillation: Inflammation in Disguise?
Lappegård, K. T., Hovland, A., Pop, G., & Mollnes, T. E. (2013) · Scandinavian Journal of Immunology · doi:10.1111/sji.12061 · Cited by 18
Inhibition of the renin–angiotensin–aldosterone system
Volpe, M., Danser, A. H. J., Ménard, J., Waeber, B., Mueller, D. N., Maggioni, A. P., & Ruilope, L. M. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834f6e00 · Cited by 18
Shin, J., Park, J. B., Kim, K., Kim, J. H., Yang, D. H., Pyun, W. B., Kim, Y. G., Kim, G., & Chae, S. C. (2015) · Clinical Hypertension · doi:10.1186/s40885-014-0014-1 · Cited by 18
Biomarkers of Atrial Fibrillation in Metabolic Syndrome
Georgakopoulos, C., Vlachopoulos, C. V., Lazaros, G., & Tousoulis, D. M. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171012105528 · Cited by 18
Pharmacologic Prevention of Incident Atrial Fibrillation
Dewland, T. A., Soliman, E. Z., Yamal, J., Davis, B. R., Alonso, Á., Albert, C. M., Simpson, L. M., Haywood, L. J., & Marcus, G. M. (2017) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.117.005463 · Cited by 18
Yang, B., Jiang, Q. L., He, S., Li, T., Ou, X., Chen, T., Fan, X., Jiang, F., Zeng, X., Huang, C. L.-H., et al. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.11.001 · Cited by 18
β-Blockers and Atrial Fibrillation: Hypertension and Other Medical Conditions Influencing Their Use
Dorian, P., & Angaran, P. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.09.029 · Cited by 18
Clinical trials, the renin angiotensin system and atrial fibrillation
Birnie, D. H., Gollob, M. H., & Healey, J. S. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000231408.69307.9b · Cited by 18
The Emergency Department: First Line of Defense in Preventing Secondary Stroke
Ovbiagele, B. I. (2006) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2006.tb01676.x · Cited by 18
The effects of losartan on signal-averaged P wave in patients with atrial fibrillation
Nomura, M., Kawano, T., Nakayasu, K., & Nakaya, Y. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.03.106 · Cited by 18
Left Atrial Remodeling and Response to Valsartan in the Prevention of Recurrent Atrial Fibrillation
Staszewsky, L. I., Wong, M., Masson, S., Raimondi, E., Gramenzi, S., Proietti, G., Bicego, D., Emanuelli, C., Pulitanò, G., Taddei, F., et al. (2011) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.111.965954 · Cited by 17
Impaired endothelial function in lone atrial fibrillation
Polovina, M. M., Potpara, T., Giga, V. L., Stepanović, J., & Ostojić, M. (2013) · Vojnosanitetski pregled · doi:10.2298/vsp110429016p · Cited by 17
Verdecchia, P., Reboldi, G., Pasquale, G. D., Mazzotta, G., Ambrosio, G., Yang, S., Pogue, J. M., Wallentin, L. C., Ezekowitz, M. D., Connolly, S. J., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.10.045 · Cited by 17
The role of physical activity in the prevention of stroke.
Chrysohoou, C. A., Pitsavos, C., Kokkinos, P. F., Panagiotakos, D. B., Singh, S., & Stefanadis, C. (2005) · PubMed · Cited by 17
Mourtzinis, G., Schiöler, L., Kahan, T., Boström, K. B., Hjerpe, P., Hasselström, J., & Manhem, K. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317708266 · Cited by 16
De‐An, P., Li, L., Xu, Z., Jin‐Yu, H., Zheng-Ming, X., Wang, M., Qiang, Y., & Shi‐eng, H. (2010) · Clinical Cardiology · doi:10.1002/clc.20689 · Cited by 16
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation
Okin, P. M., Hille, D. A., Wachtell, K., Kjeldsen, S. E., Boman, K., Dahlöf, B., & Devereux, R. B. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000559 · Cited by 16
Self-citationLee, J., Choi, E. H., Son, J., Youn, Y. J., Ahn, S. G., Ahn, M., Kim, J., Lee, S., Yoon, J., Ryu, D. R., et al. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa060 · Cited by 16
Review: Atrial fibrillation and renin-angiotensin system
Serra, J. L. P., & Bendersky, M. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708092111 · Cited by 16
Lewalter, T., Tebbenjohanns, J., Wichter, T., Antz, M., Geller, J. C., Seidl, K., Gulba, D. C., Röhrig, F., & Willems, S. (2008) · Der Kardiologe · doi:10.1007/s12181-008-0080-2 · Cited by 16
Lip, G. Y. H., Frison, L., & Grind, M. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01780.x · Cited by 17
González‐Juanatey, J. R., Cea‐Calvo, L., Bertoméu, V., & Aznar, J. (2007) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(07)60127-3 · Cited by 16
Angiotensin II Receptor Antagonists
Tocci, G., Giovannelli, F., & Facciolo, C. (2007) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/00151642-200714010-00006 · Cited by 16
The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature
Făgărășan, A., Săsăran, M. O., Gozar, L., Crauciuc, A., & Bănescu, C. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310511 · Cited by 15
Non-Antiarrhythmic Drugs to Prevent Atrial Fibrillation
Moro, C., Hernández‐Madrid, A., & Matía, R. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/11537270-000000000-00000 · Cited by 15
Galectin-3 in patients undergoing ablation of atrial fibrillation
Clémenty, N., Piver, É., Benhenda, N., Bernard, A. B., Pierre, B., Siméon, E., Fauchier, L., Pagès, J., & Babuty, D. (2014) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2014.10.003 · Cited by 15
Lower heart rates and beta-blockers are associated with new-onset atrial fibrillation
Habel, N., de Lavallaz, J. D. F., Infeld, M. M., Koehler, J. L., Ziegler, P., Lustgarten, D. L., & Meyer, M. (2023) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2023.200182 · Cited by 15
Atrial Fibrillation and Hypertension: “Quo Vadis”
Kwon, Y., Walker, M., Patel, P., Kwon, O., Koene, R. J., & Duprez, D. A. (2022) · Current Hypertension Reviews · doi:10.2174/1573402118666220112122403 · Cited by 15
Martín-Rioboó, E., Criado, E. G., de Torres, L. Á. P., Cea‐Calvo, L., Sánchez, M. A., Granados, A. L., Fernández, T. U., Matarin, L. G., & Díaz, R. M. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2008.07.011 · Cited by 15
Cardioembolic Stroke: Call for a Multidisciplinary Approach
Babarro, E. G., Rego, A. R., & González‐Juanatey, J. R. (2009) · Cerebrovascular Diseases · doi:10.1159/000200444 · Cited by 15
Jong, G., Chen, H., Li, S., & Liou, Y. (2014) · Hypertension Research · doi:10.1038/hr.2014.104 · Cited by 15
Hypertension treatment and implications of recent cardiovascular outcome trials
Weber, M. A. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000220102.35025.eb · Cited by 15
Tanabe, Y., Kawamura, Y., Sakamoto, N., Sato, N., Kikuchi, K., & Hasebe, N. (2009) · International Heart Journal · doi:10.1536/ihj.50.445 · Cited by 15
Chaugai, S., Sherpa, L. Y., Sepehry, A. A., Arima, H., & Wang, D. W. (2016) · Medicine · doi:10.1097/md.0000000000004059 · Cited by 15
Management of cardiovascular risk with RAS inhibitor/CCB combination therapy
Dahlöf, B. (2008) · Journal of Human Hypertension · doi:10.1038/jhh.2008.88 · Cited by 15
Self-citationUtility of Brain Natriuretic Peptide as a Predictor of Atrial Fibrillation After Cardiac Operations
Tavakol, M., Hassan, K. Z., Abdula, R., Briggs, W., Oribabor, C. E., Tortólani, A. J., Sacchi, T. J., Lee, L. Y., & Heitner, J. F. (2009) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2009.04.021 · Cited by 15
Inhibition of the Renin-Angiotensin System for Prevention of Atrial Fibrillation
Zografos, T. A., & Katritsis, D. G. (2010) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2010.02832.x · Cited by 15
Klemm, H. U., Heitzer, T. A., Ruprecht, U., Meinertz, T., & Ventura, R. (2010) · Cardiology · doi:10.1159/000318016 · Cited by 15
Early management of atrial fibrillation: from imaging to drugs to ablation
Shah, A. J., Liu, X., Jadidi, A., & Haı̈ssaguerre, M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.49 · Cited by 14
Signal-averaged P wave duration and the long-term risk of permanent atrial fibrillation
Dixen, U., Larsen, M. V., Ravn, L. S., Parner, J., & Jensen, G. B. (2008) · Scandinavian Cardiovascular Journal · doi:10.1080/14017430701652282 · Cited by 14
Metadata
- Authors
- Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., Nieminen, M. S., & Devereux, R. B.
- Affiliations
- Cornell University (US)
- Helsinki University Hospital (FI)
- Haukeland University Hospital (NO)
- Glostrup Hospital (DK)
- Sahlgrenska University Hospital (SE)
- University of Michigan (US)
- Oslo University Hospital (NO)
- University Hospital of Umeå (SE)
- Corresponding author
- Wachtell, Kristian
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 45
- Issue
- 5
- Pages
- 712-719
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2147918774
- Cited by
- 826
- References
- 27
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 16 · 2023: 17 · 2022: 13 · 2021: 20 · 2020: 20 · 2019: 16 · 2018: 30 · 2017: 32 · 2016: 31 · 2015: 29 · 2014: 36 · 2013: 40 · 2012: 33
- FWCI
- 64.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Rigshospitalet
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- angiotensin II receptor blockade, losartan, atenolol, beta-blockers, stroke prevention, hypertension, left ventricular hypertrophy, antihypertensive therapy, heart failure hospitalization, cardiovascular events, life studies, sinus rhythm maintenance, RAS inhibition, renin-angiotensin system
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Atenolol, Atrial Fibrillation, Cause of Death, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Prospective Studies, Risk Factors, Survival Rate, Hypertrophy, Left Ventricular, Losartan, Stroke, Angiotensin II Type 1 Receptor Blockers, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
